Moreover, the similar effects of PLUM-EZH2 targeting s-ASOs with that of EZH2 inhibitor (tazemetostat) in the destabilization of EZH2 activity and abrogation of chemoresistance support the possible use of PLUM as an alternative target to overcome the resistance mechanisms associated with known EZH2 catalytic inhibitors in MM. The gene discussed is EZH2; the disease is Miyoshi myopathy.